7 recruiting, 5 active not recruiting, 2 completed, 1 not yet recruiting. 15 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Recruiting 7, Active not recruiting 5, Completed 2, Not yet recruiting 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 2 |
Follow FDG-Positron Emission Tomography: new trials by email Literature Review of FDG-Positron Emission Tomography trials Research Report on FDG-Positron Emission Tomography
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-04 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 24 | 2027-02-26 | 2026-11-04 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 27 | 2025-05-29 | 2026-01-30 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 474 | 2025-02-06 | 2026-11-03 |
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial Antiandrogen Therapy, Bone Scan, Computed Tomography - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2024-02-18 | 2026-10-08 |
| Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Computed Tomography - Lung Adenocarcinoma, Lung Large Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2022-12-15 | 2026-09-04 |
| A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-06-16 | 2026-10-07 |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin - Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Completed | University of Washington | 42 | 2022-03-23 | 2026-05-13 |
| Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 2 | Active not recruiting | Children's Oncology Group | 41 | 2020-12-31 | 2025-10-27 |
| Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-11-04 | 2026-09-08 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
Neuroblastoma (3) · Prostatic Neoplasms (3) · Ganglioneuroblastoma (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Adenocarcinoma of Lung (1) · Burkitt Lymphoma (1) · Carcinoma (1) · Central Nervous System Neoplasms (1) · Ependymoma (1) · Glioma (1) · Hepatoblastoma (1) · Histiocytosis, Langerhans-Cell (1) · Leukemia, Biphenotypic, Acute (1) · Lung Neoplasms (1)
National Cancer Institute (NCI) (8) · University of Washington (2) · Alliance for Clinical Trials in Oncology (1) · Children's Oncology Group (1) · Mayo Clinic (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1)
United States (14) · Puerto Rico (2) · Australia (1) · Canada (1) · Guam (1) · New Zealand (1)
Adel Mandl (1) · Afshin Dowlati (1) · Ami V Desai (1) · David M. Routman, M.D. (1) · David VanderWeele, MD, PhD (1) · Erin H Breese (1) · Juneko E Grilley-Olson (1) · Kieuhoa T Vo (1) · Muhamed Baljevic (1) · Murali Janakiram (1) · Rana McKay, MD (1) · Ryan Lynch (1) · Ryan Lynch, MD (1) · Stephen E Spurgeon (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 36521030, PMID 40802906, PMID 41785440, PMID 42600120
U10CA180886 (4), U10CA180820 (2), P30CA043703 (1), P30CA060553 (1), U10CA180821 (1), UM1CA186691 (1)